If ongoing studies demonstrate favorable safety and efficacy profiles, CAR T-cell therapy may establish a novel treatment ...
A large study finds that nearly half of CAR T-cell therapy recipients develop a respiratory viral infection, and most infections occur after day 100.
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...
The first single-cell and spatial atlas of the developing human meninges shows that meningioma tumours transcriptionally ...
Oncology demand, CAR-T innovation, regulatory approvals and efficient manufacturing position North America and autologous immunotherapies as key growth opportunitiesDublin, Oct. 08, 2026 (GLOBE ...
ADC Therapeutics expects third-quarter 2026 net product revenue from ZYNLONTA of approximately $21 million. The company reported cash and cash equivalents of $189.2 million as of September 30, 2026 ...
WALTHAM - Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmun ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, ...
Why Is CRBU Stock Falling Today? Caribou Biosciences Falls After Halting CAR-T Programs and Exploring Strategic Alternatives ...
According to the experts, clinicians should consider CAR T-cell therapy for patients with severe autoimmune disease that ...
For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results